BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $21

Benzinga · 1d ago
BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $21.